The protective effect of angiotensin converting enzyme inhibition in experimental renal fibrosis in mice is not mediated by bradykinin B2 receptor activation

Summary

Unilateral ureteral obstruction (UUO) is an animal model of accelerated renal tubulointerstitial fibrosis. We have recently shown, using this model, that mice lacking the bradykinin B2-receptor (B2^-/- ) were more susceptible than control animals to the development of tubulointerstitial fibrosis. Angiotensin converting enzyme (ACE) inhibition slows down UUO-induced renal fibrosis. Since ACE-inhibition increases bradykinin and decreases angiotensin II concentrations we have verified if bradykinin is involved in the antifibrotic effects of ACE-inhibition using the UUO-model and B2^-/- mice. Surprisingly, although ACE-inhibition significantly reduced renal fibrosis, no difference was observed between the degree of tubulointerstitial fibrosis, macrophage infiltration and cell proliferation between ACE-inhibitor treated B2^+/+ and B2^-/- mice suggesting the absence of a role of the B2-receptor in the antifibrotic effects of ACE-inhibition. This was confirmed at the level of bradykinin-induced activity of enzymes involved in the degradation of the extracellular matrix. However in both mouse strains, ACE-inhibitors were more efficient than AT1 receptor antagonists.

Theme paper: Part of this paper was originally presented at the joint meetings of the 16th International Congress of the International Society of Fibrinolysis and Proteolysis (ISFP) and the 17th International Fibrinogen Workshop of the International Fibrinogen Research Society (IFRS) held in Munich, Germany, September, 2002.

Keywords

ACE-inhibition - bradykinin - renal fibrosis

• References

• 1 Strutz F. Potential methods to prevent interstitial fibrosis in renal disease. Expert Opin Investig Drugs 2001; 10: 1-13.
• 2 Jones CL, Buch S, Post M, McCulloch L, Liu E, Eddy AA. Renal extracellular matrix accumulation in acute puromycin aminonucleoside nephrosis in rats. Am J Pathol 1992; 141: 1381-96.
• 3 Müller GA, Schettler V, Müller CA, Strutz F. Renal fibrosis: prevention of progression- how far are we?. Kidney Int 1996; 49 (54) Suppl S75-882.
• 4 Fioretto P, Steffes MW, Sutherland DE, Goetz FC, Mauer M. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998; 339: 69-75.
• 5 Schanstra JP, Neau E, Drogoz P, Arevalo Gomez M, Lopez Novoa J, Calise D, Pecher C, Praddaude F, Bader M, Girolami JP, Bascands JL. Renal bradykinin B2-receptor activation reduces renal fibrosis. J Clin Invest 2002; 110: 371-9.
• 6 Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-62.
• 7 Ishidoya S, Morrissey J, McCracken R, Reyes A, Klahr S. Angiotensin II receptor antagonist ameliorates renal tubulointerstitial fibrosis caused by unilateral ureteral obstruction. Kidney Int 1995; 47: 1285-94.
• 8 Klahr S, Morrissey JJ. Comparative study of ACE inhibitors and angiotensin II receptors antagonists in interstitial scarring. Kidney Int 1997; 63S: S-111-4.
• 9 Borkowski JA, Ransom RW, Seabrook GR, Trumbauer M, Chen H, Hill RG, Strader CD, Hess JF. Targeted disruption of a B2 bradykinin receptor gene in mice eliminates bradykinin action in smooth muscle and neurons. J Biol Chem 1995; 270: 13706-10.
• 10 Wakeland E, Morel L, Achey K, Yui M, Longmate J. Speed congenics: a classic technique in the fast lane (relatively speaking). Immunol Today 1997; 18: 472-7.
• 11 Morrissey JJ, Ishidoya S, McCracken R, Klahr S. Nitric oxide generation ameliorates the tubulointerstitial fibrosis of obstructive nephropathy. J Am Soc Nephrol 1996; 7: 2202-12.
• 12 Campbell DJ, Kladis A, Duncan AM. Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension 1994; 23: 439-49.
• 13 Rhaleb NE, Peng H, Alfie ME, Shesely EG, Carretero OA. Effect of ACE inhibitor on DOCA-salt- and aortic coarctation-induced hypertension in mice: do kinin B2-receptors play a role?. Hypertension 1999; 33: 329-34.
• 14 Emanueli C, Angioni GR, Anania V, Spissu A, Madeddu P. Blood pressure responses to acute or chronic captopril in mice with disruption of bradykinin B2-receptor gene. J Hypertens 1997; 15: 1701-6.
• 15 Silvestre JS, Bergaya S, Tamarat R, Duriez M, Boulanger CM, Levy I B. Proangiogenic effect of angiotensin-converting enzyme inhibition is mediated by the bradykinin B(2) receptor pathway. Circ Res 2001; 89: 678-83.
• 16 Yang XP, Liu YH, Mehta D, Cavasin MA, Shesely E, Xu J, Liu F, Carretero OA. Diminished cardioprotective response to inhibition of angiotensin-converting enzyme and angiotensin II type 1 receptor in B(2) kinin receptor gene knockout mice. Circ Res 2001; 88: 1072-9.
• 17 Emanueli C, Bonaria Salis M, Figueroa C, Chao J, Chao L, Gaspa L, Capogrossi MC, Madeddu P. Participation of kinins in the cap-topril-induced inhibition of intimal hyperplasia caused by interruption of carotid blood flow in the mouse. Br J Pharmacol 2000; 130: 1076-82.
• 18 Liu YH, Yang XP, Sharov VG, Nass O, Sabbah HN, Peterson E, Carretero OA. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors. J Clin Invest 1997; 99: 1926-35.
• 19 Rhaleb NE, Yang XP, Scicli AG, Carretero OA. Role of kinins and nitric oxide in the anti-hypertrophic effect of ramipril. Hypertension 1994; 23: 865-8.
• 20 El-Dahr SS, Gee J, Dipp S, Hanss BG, Vari RC, Chao J. Upregulation of renin-angiotensin system and downregulation of kallikrein in obstructive nephropathy. Am J Physiol 1993; 264: F874-78.
• 21 Klahr S. Obstructive nephropathy. Kidney Int 1998; 54: 286-300.
• 22 Marceau F, Hess JF, Bachvarov DR. The B1 receptors for kinins. Pharmacol Rev 1998; 50: 357-86.
• 23 Marin-Castano ME, Schanstra JP, Neau E, Praddaude F, Pecher C, Ader JL, Girolami JP, Bascands JL. Induction of functional bradykinin B(1)-receptors in normotensive rats and mice under chronic angiotensin-converting enzymeinhibitor treatment. Circulation 2002; 105: 627-32.
• 24 Madeddu P, Varoni MV, Palomba D, Emanueli C, Demontis MP, Glorioso N, Dessi-Fulgheri P, Sarzani R, Anania V. Cardiovascular phenotype of a mouse strain with disruption of bradykinin B2-receptor gene. Circulation 1997; 96: 3570-8.
• 25 Fern RJ, Yesko CM, Thornhill BA, Kim HS, Smithies O, Chevalier RL. Reduced angiotensinogen expression attenuates renal interstitial fibrosis in obstructive nephropathy in mice. J Clin Invest 1999; 103: 39-46.
• 26 Skidgel RA, Engelbrecht S, Johnson AR, Erdos EG. Hydrolysis of substance p and neurotensin by converting enzyme and neutral endopeptidase. Peptides 1984; 5: 769-76.
• 27 Skidgel RA, Erdos EG. The broad substrate specificity of human angiotensin I converting enzyme. Clin Exp Hypertens 1987; 9: 243-59.
• 28 Yokosawa H, Endo S, Ogura Y, Ishii S. A new feature of angiotensin-converting enzyme in the brain: hydrolysis of substance P. Biochem Biophys Res Commun 1983; 116: 735-42.
• 29 Emanueli C, Salis MB, Pinna A, Stacca T, Milia AF, Spano A, Chao J, Chao L, Sciola L, Madeddu P. Prevention of diabetes-induced microangiopathy by human tissue kallikrein gene transfer. Circulation 2002; 106: 993-9.